These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21521159)

  • 1. Targeting phosphoinositide 3-kinase pathways in pancreatic cancer--from molecular signalling to clinical trials.
    Falasca M; Selvaggi F; Buus R; Sulpizio S; Edling CE
    Anticancer Agents Med Chem; 2011 Jun; 11(5):455-63. PubMed ID: 21521159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer.
    Ebrahimi S; Hosseini M; Shahidsales S; Maftouh M; Ferns GA; Ghayour-Mobarhan M; Hassanian SM; Avan A
    Curr Med Chem; 2017; 24(13):1321-1331. PubMed ID: 28176634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
    Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
    Su CC
    Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
    Wolin EM
    Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.
    Conway JR; Herrmann D; Evans TJ; Morton JP; Timpson P
    Gut; 2019 Apr; 68(4):742-758. PubMed ID: 30396902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
    Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
    Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
    Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
    Expert Opin Ther Targets; 2016 Jul; 20(7):831-42. PubMed ID: 26873344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.
    Pettazzoni P; Viale A; Shah P; Carugo A; Ying H; Wang H; Genovese G; Seth S; Minelli R; Green T; Huang-Hobbs E; Corti D; Sanchez N; Nezi L; Marchesini M; Kapoor A; Yao W; Francesco ME; Petrocchi A; Deem AK; Scott K; Colla S; Mills GB; Fleming JB; Heffernan TP; Jones P; Toniatti C; DePinho RA; Draetta GF
    Cancer Res; 2015 Mar; 75(6):1091-101. PubMed ID: 25736685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulation of PI3K/Akt/mTOR signaling pathways by isoflavones and its implication in cancer treatment.
    Ahmad A; Biersack B; Li Y; Kong D; Bao B; Schobert R; Padhye SB; Sarkar FH
    Anticancer Agents Med Chem; 2013 Sep; 13(7):1014-24. PubMed ID: 23272911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities.
    Hubbard PA; Moody CL; Murali R
    Front Physiol; 2014; 5():478. PubMed ID: 25566081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway.
    Saleem M; Kaur S; Kweon MH; Adhami VM; Afaq F; Mukhtar H
    Carcinogenesis; 2005 Nov; 26(11):1956-64. PubMed ID: 15958516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
    Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
    Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway.
    Chen Y; Bai X; Zhang Q; Wen L; Su W; Fu Q; Sun X; Lou Y; Yang J; Zhang J; Chen Q; Wang J; Liang T
    Cancer Lett; 2016 Sep; 380(1):98-105. PubMed ID: 27339327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desumoylating Isopeptidase 2 (DESI2) Inhibits Proliferation and Promotes Apoptosis of Pancreatic Cancer Cells through Regulating PI3K/AKT/mTOR Signaling Pathway.
    Ou X; Zhang GT; Xu Z; Chen JS; Xie Y; Liu JK; Liu XP
    Pathol Oncol Res; 2019 Apr; 25(2):635-646. PubMed ID: 30411297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.